Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Receivables - Net: 2013-2024

Historic Receivables - Net for Amphastar Pharmaceuticals (AMPH) over the last 12 years, with Dec 2024 value amounting to $136.3 million.

  • Amphastar Pharmaceuticals' Receivables - Net rose 5.14% to $146.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $146.8 million, marking a year-over-year increase of 5.14%. This contributed to the annual value of $136.3 million for FY2024, which is 18.57% up from last year.
  • Per Amphastar Pharmaceuticals' latest filing, its Receivables - Net stood at $136.3 million for FY2024, which was up 18.57% from $114.9 million recorded in FY2023.
  • In the past 5 years, Amphastar Pharmaceuticals' Receivables - Net registered a high of $136.3 million during FY2024, and its lowest value of $66.0 million during FY2020.
  • Its 3-year average for Receivables - Net is $113.3 million, with a median of $114.9 million in 2023.
  • Data for Amphastar Pharmaceuticals' Receivables - Net shows a peak YoY spiked of 45.46% (in 2020) over the last 5 years.
  • Yearly analysis of 5 years shows Amphastar Pharmaceuticals' Receivables - Net stood at $66.0 million in 2020, then climbed by 19.39% to $78.8 million in 2021, then climbed by 12.69% to $88.8 million in 2022, then grew by 29.43% to $114.9 million in 2023, then climbed by 18.57% to $136.3 million in 2024.